Half Year 2024 Vivoryon Therapeutics NV Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Lucy Codrington - Jefferies - Analyst : Just to begin with, I guess, now you know what you know from the additional analysis of VIVIAD, what are you hoping to find out from the -- from your findings when you analyze VIVA-MIND, just trying work out what could be incremental there. Secondly, I think on the last call, you acknowledge that partnership discussions have not included the additional data and diabetics that you were presenting. So since that data were disclosed, could you update us on how your partnership discussions have progressed? And then Finally, on the design of the study for diabetic kidney disease, will patients be stratified by GLP-1 use just considering the fact that the proposed kind of anti-inflammatory effect of these has -- looks to be independent of the weight loss. So just not to kind of mix up any anti-inflammatory effect of those with that potentially of varo?

Question: Lucy Codrington - Jefferies - Analyst : Yes, it does. Great.

Question: Christian Ehmann - Warburg Research - Analyst : I would like to have a question regarding the patent life. So under which circumstances would you be able to extend the patent protection to 2044, as you've mentioned in your slides and what kind of patent protection would have entailed? Are we talking about additional composition of meta patents? Or is it more like in the area of delivery and so forth?

Question: Christian Ehmann - Warburg Research - Analyst : What's the reasonable time line to expect a decision on this?